interferon in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Davoudi-Monfared, 2020 0.30 [0.11; 0.83]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Pandit, 2021 0.95 [0.02; 50.33]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
0.91 [0.25 ; 3.29 ] Davoudi-Monfared, 2020, Kalil (ACTT-3), 2021, Pandit, 2021, Shashi Bhushan, 2021 4 51% 1,339 moderate not evaluable deathsdetailed results Darazam (COVIFERON Interferon beta-1a), 2021 0.31 [0.07; 1.25]
Darazam (COVIFERON Interferon beta-1b), 2021 0.52 [0.14; 1.92]
Davoudi-Monfared, 2020 0.38 [0.16; 0.87]
Esquivel-Moynelo, 2020 1.10 [0.02; 57.31]
Fu, 2020 1.00 [0.02; 51.66]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Pandit, 2021 0.95 [0.02; 50.33]
Rahmani, 2020 0.29 [0.05; 1.56]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
SOLIDARITY (interferon), 2020 1.16 [0.96; 1.40]
SPRINTER, 2022 0.79 [0.38; 1.66]
Synairgen SG016, 2020 0.16 [0.01; 3.31]
0.74 [0.48 ; 1.14 ] Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Davoudi-Monfared, 2020, Esquivel-Moynelo, 2020, Fu, 2020, Kalil (ACTT-3), 2021, Pandit, 2021, Rahmani, 2020, Shashi Bhushan, 2021, SOLIDARITY (interferon), 2020, SPRINTER, 2022, Synairgen SG016, 2020 12 34% 6,463 moderate critical deaths (time to event analysis only)detailed results Davoudi-Monfared, 2020 0.38 [0.16; 0.87]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
0.76 [0.17 ; 3.38 ] Davoudi-Monfared, 2020, Kalil (ACTT-3), 2021 2 75% 1,061 serious not evaluable clinical deteriorationdetailed results Esquivel-Moynelo, 2020 2.29 [0.20; 26.58]
SPRINTER, 2022 0.69 [0.43; 1.11]
Synairgen SG016, 2020 0.50 [0.18; 1.38]
0.68 [0.44 ; 1.04 ] Esquivel-Moynelo, 2020, SPRINTER, 2022, Synairgen SG016, 2020 3 0% 787 NA not evaluable clinical improvementdetailed results Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Davoudi-Monfared, 2020 1.10 [0.64; 1.88]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
Synairgen SG016, 2020 2.32 [1.07; 5.04]
1.28 [0.87 ; 1.90 ] Darazam (COVIFERON Interferon beta-1a), 2021, Davoudi-Monfared, 2020, Kalil (ACTT-3), 2021, Shashi Bhushan, 2021, Synairgen SG016, 2020 5 58% 1,332 moderate not evaluable clinical improvement (14-day)detailed results Kalil (ACTT-3), 2021 1.01 [0.79; 1.29]
Pandit, 2021 8.77 [0.94; 81.67]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
1.16 [0.50 ; 2.72 ] Kalil (ACTT-3), 2021, Pandit, 2021, Shashi Bhushan, 2021 3 50% 1,250 moderate not evaluable clinical improvement (28-day)detailed results Synairgen SG016, 2020 3.15 [1.39; 7.14]
3.15 [1.39 ; 7.14 ] Synairgen SG016, 2020 1 0% 101 NA not evaluable clinical improvement (7-day)detailed results Shashi Bhushan, 2021 1.91 [1.03; 3.53]
1.91 [1.03 ; 3.53 ] Shashi Bhushan, 2021 1 0% 222 NA not evaluable clinical improvement (time to event analysis only)detailed results Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Darazam (COVIFERON Interferon beta-1b), 2021 1.42 [0.63; 3.18]
Davoudi-Monfared, 2020 1.10 [0.64; 1.88]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Rahmani, 2020 3.41 [1.33; 8.73]
SPRINTER, 2022 1.02 [0.81; 1.28]
1.21 [0.94 ; 1.55 ] Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Davoudi-Monfared, 2020, Kalil (ACTT-3), 2021, Rahmani, 2020, SPRINTER, 2022 6 57% 1,819 moderate serious death or ventilationdetailed results SOLIDARITY (interferon), 2020 1.05 [0.90; 1.23]
SPRINTER, 2022 0.85 [0.45; 1.61]
Synairgen SG016, 2020 0.38 [0.09; 1.63]
1.00 [0.79 ; 1.26 ] SOLIDARITY (interferon), 2020, SPRINTER, 2022, Synairgen SG016, 2020 3 9% 4,723 moderate not evaluable hospital dischargedetailed results Davoudi-Monfared, 2020 1.96 [0.76; 5.03]
Rahmani, 2020 3.44 [0.64; 18.49]
SPRINTER, 2022 1.06 [0.89; 1.27]
Synairgen SG016, 2020 1.63 [0.61; 4.35]
1.31 [0.88 ; 1.94 ] Davoudi-Monfared, 2020, Rahmani, 2020, SPRINTER, 2022, Synairgen SG016, 2020 4 25% 871 low not evaluable hospitalizationdetailed results Jagannathan, 2020 1.00 [0.14; 7.34]
1.00 [0.14 ; 7.34 ] Jagannathan, 2020 1 0% 120 NA not evaluable mechanical ventilationdetailed results Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.27; 3.67]
Darazam (COVIFERON Interferon beta-1b), 2021 1.00 [0.27; 3.67]
Davoudi-Monfared, 2020 0.72 [0.29; 1.76]
Rahmani, 2020 0.29 [0.05; 1.56]
0.74 [0.41 ; 1.34 ] Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Davoudi-Monfared, 2020, Rahmani, 2020 4 0% 227 moderate not evaluable Recovery (time to event analysis only)detailed results SPRINTER, 2022 1.02 [0.81; 1.28]
1.02 [0.81 ; 1.28 ] SPRINTER, 2022 1 0% 623 NA not evaluable viral clearance detailed results Esquivel-Moynelo, 2020 3.26 [1.53; 6.95]
Jagannathan, 2020 0.81 [0.56; 1.18]
Pandit, 2021 2.33 [0.55; 9.83]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
1.93 [0.83 ; 4.49 ] Esquivel-Moynelo, 2020, Jagannathan, 2020, Pandit, 2021, Shashi Bhushan, 2021 4 83% 464 moderate not evaluable viral clearance (time to event analysis only)detailed results Esquivel-Moynelo, 2020 3.26 [1.53; 6.95]
Jagannathan, 2020 0.81 [0.56; 1.18]
1.56 [0.40 ; 6.09 ] Esquivel-Moynelo, 2020, Jagannathan, 2020 2 90% 183 moderate not evaluable viral clearance by day 14detailed results Esquivel-Moynelo, 2020 5.90 [0.28; 122.94]
Pandit, 2021 10.23 [1.12; 93.35]
Shashi Bhushan, 2021 0.00 [0.00; 0.01]
0.55 [0.00 ; 227.28 ] Esquivel-Moynelo, 2020, Pandit, 2021, Shashi Bhushan, 2021 3 96% 1,422 moderate not evaluable viral clearance by day 7detailed results Esquivel-Moynelo, 2020 3.09 [1.04; 9.17]
Pandit, 2021 2.33 [0.55; 9.83]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
2.78 [1.65 ; 4.68 ] Esquivel-Moynelo, 2020, Pandit, 2021, Shashi Bhushan, 2021 3 0% 344 moderate not evaluable ICU admissiondetailed results Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.21; 4.71]
Darazam (COVIFERON Interferon beta-1b), 2021 0.46 [0.11; 1.94]
Rahmani, 2020 0.37 [0.14; 1.00]
0.49 [0.24 ; 1.00 ] Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Rahmani, 2020 3 0% 146 moderate not evaluable off oxygenationdetailed results Davoudi-Monfared, 2020 8.57 [1.43; 51.36]
8.57 [1.43 ; 51.36 ] Davoudi-Monfared, 2020 1 0% 32 NA not evaluable recoverydetailed results Synairgen SG016, 2020 2.19 [1.03; 4.67]
2.19 [1.03 ; 4.67 ] Synairgen SG016, 2020 1 0% 101 NA not evaluable serious adverse eventsdetailed results Jagannathan, 2020 1.00 [0.14; 7.34]
Pandit, 2021 0.95 [0.02; 50.33]
0.99 [0.17 ; 5.88 ] Jagannathan, 2020, Pandit, 2021 2 0% 159 moderate not evaluable superinfectiondetailed results Davoudi-Monfared, 2020 2.41 [0.75; 7.73]
Rahmani, 2020 0.18 [0.02; 1.59]
0.77 [0.06 ; 9.89 ] Davoudi-Monfared, 2020, Rahmani, 2020 2 76% 147 serious not evaluable adverse eventsdetailed results Esquivel-Moynelo, 2020 1.33 [0.45; 3.92]
Jagannathan, 2020 1.33 [0.63; 2.78]
Pandit, 2021 1.68 [0.47; 5.97]
1.39 [0.80 ; 2.40 ] Esquivel-Moynelo, 2020, Jagannathan, 2020, Pandit, 2021 3 0% 222 moderate not evaluable 0.2 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-19 10:45 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 517,881,904,882,897,896,899,1235,898,687,740,883,947
- roots T: 290
